Talk Title: Disease Biomarkers for Bipolar Disorder – from laboratory to patient beside-
Professor Sabine Bahn is a practising psychiatrist, Chair in Neurotechnology and Director of the Cambridge Centre for Neuropsychiatric Research at Cambridge University. Her main research interests are to understand the molecular basis of neuropsychiatric disorders, with a focus on schizophrenia and mood disorders. Professor Bahn has published many articles in high impact journals and has co-founded 2 spin-out companies. Over the last 15 years her work has focused on translational research with the aim to develop blood-based diagnostic tests and new treatments for mental disorders, which should also aid in the development of much needed personalised treatment approaches. In 2015 she was elected as Fellow of the Royal Society of Biology. She is a fellow of Lucy Cavendish College.
Disease Biomarkers for Bipolar Disorder – from laboratory to patient beside-
The diagnosis of Bipolar Disorder (BD) and Major Depression (MDD) is based on the subjective reporting of symptoms.
Around 60% of BD patients are misdiagnosed and the average time until a correct diagnosis is achieved is 9.6 years. Objective blood-based biomarkers could help in the differential diagnosis of BD.
We have previously identified a panel of 20 protein biomarkers in serum capable of differentiating BD from MDD patients using a multiplex ELISA platform. However, multiplexed ELISA is costly and antibody batch variation is associated with problems in reproducibility.
Thus, we are now developing a two-stage diagnostic approach combining a highly scalable digital clinical app, which assesses symptoms and demographic patient characteristics, in conjunction with a biomarker test using multiplex MRM mass spectrometry on self-collected dried blood spots (DBS).
If our results can be validated, this novel diagnostic approach would represent a cost-effective solution with the potential to dramatically reduce misdiagnosis rates and improve patient outcomes.